FIELD: pharmaceutics.
SUBSTANCE: present invention relates to novel compounds of formula I or pharmaceutically acceptable esters or phosphate, which are used for treating squamous cell carcinoma/hepatoma, to a pharmaceutical composition based thereon, to a method of treating squamous cell carcinoma/hepatoma and to a method of producing compounds of formula I. In formula I : R′, R denote hydrogen or C1-3 alkyl; R1, R2, R3 each independently represents hydrogen, C1-3 alkyl or 
; and at least one from R1, R2, R3 is 
; R4, R5, R6 each independently represents hydrogen, C1-3 alkyl, (CH2)n-CH2OH or (CHOH)n-CH2OH, n = 0-3; and at least one of R4, R5, R6 is (CH2)n-CH2OH or (CHOH)n-CH2OH, n = 0 to 3. Invention also relates to intermediate compounds of formula II, where R′, R denote hydrogen or C1-3 alkyl; X1, X2, X3 independently represents hydrogen, C1-3 alkyl or 
, where R7 and R8 each independently denotes hydrogen or C1-3 alkyl; at least one of X1, X2, X3 is 
.
EFFECT: treatment of squamous cell carcinoma/hepatoma.
9 cl, 7 dwg, 3 tbl, 22 ex
| Title | Year | Author | Number |
|---|---|---|---|
| QUINOLINE DERIVATIVES AS SMO INHIBITORS | 2015 |
|
RU2695815C2 |
| THIENODIAZEPINE DERIVATIVES AND THEIR USE | 2018 |
|
RU2795005C2 |
| SYNTHESIS AND ANTICANCER ACTIVITY OF DERIVATIVES OF ARYL AND HETEROARYL QUINOLINES | 2011 |
|
RU2584688C2 |
| PDE9 INHIBITOR AND ITS USE | 2018 |
|
RU2793732C2 |
| INDOLE DERIVATIVE USED AS CRTH2 INHIBITOR | 2017 |
|
RU2756270C2 |
| HETEROCYCLIC COMPOUND, INTERMEDIATE COMPOUND, A METHOD OF ITS PRODUCTION AND ITS USE | 2019 |
|
RU2800153C2 |
| SUBSTITUTED INDOLE COMPOUNDS AS REDUCING REGULATORS OF ESTROGEN RECEPTORS | 2017 |
|
RU2722441C2 |
| PYRROLIDINE DERIVATIVES AS PPAR AGONISTS | 2017 |
|
RU2711991C1 |
| FGFR INHIBITOR AND ITS MEDICAL USE | 2018 |
|
RU2771311C2 |
| ATR INHIBITOR AND ITS USE | 2019 |
|
RU2799047C2 |
